奈达铂支气管动脉灌注联合全身化疗治疗晚期非小细胞肺癌

摘要

Objective:To evaluate the efficacy and safety of nedaplatin and docetaxel bronchial artery infusion(BAI) combined with docetaxel systemic chemotherapy in the treatments with advanced non-small cell lung cancer(NSCLC).Method:37 patients with advanced NSCLC by bronchial artery infusion of nedaplatin and docetaxel,and to give systemic chemotherapy,after finished more than two cycles to evaluate its effect and adverse reactions.Result:In 37 cases, 8 patients were CR,17 cases were PR,the effective rate was 67.6%,and the main adverse reaction was myelosuppression.Conclusion:Nedaplatin and docetaxel bronchial artery infusion combined with docetaxel systemic chemotherapy is a good curative effect,a lower adverse reaction,and can be tolerated by the patients with NSCLC.%目的：观察选择性支气管动脉灌注奈达铂及多西他赛并联合多西他赛全身化疗治疗晚期非小细胞肺癌的疗效和安全性。方法：37例晚期非小细胞肺癌患者经支气管动脉注入奈达铂和多西他赛，并给予全身化疗，每例均完成2个以上周期后评价其疗效及不良反应。结果：37例患者中，完全缓解(CR)8例，部分缓解(PR)17例，有效率为67.6%，主要不良反应为骨髓抑制。结论：奈达铂及多西他赛经支气管动脉灌注并联合多西他赛全身化疗是治疗晚期非小细胞肺癌的一种疗效好、不良反应轻、可耐受的方法。